Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 22.65% is 10% below its 5-year average of 25.17%, around the middle of its 5-year range (1.82%–38.66%).
51.33% above its 12-month average of 14.97%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 21.21%.
GROSS MARGIN
22.65%
GROSS MARGIN AVG TTM
14.97%
GROSS MARGIN AVG 3Y
25.59%
GROSS MARGIN AVG 5Y
25.17%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+51.33%
CURRENT VS 3Y AVG
-11.48%
CURRENT VS 5Y AVG
-10.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 726 covered companies
CURRENT VS SECTOR MEDIAN
-44.25%
vs the sector median at left
Market Cap
$1.70B
Gross Margin
76.47%
TTM Avg
79.35%
3Y Avg
79.86%
5Y Avg
39.87%
Market Cap
$1.73B
Gross Margin
49.52%
TTM Avg
50.81%
3Y Avg
52.12%
5Y Avg
52.25%
Market Cap
$1.73B
Gross Margin
12.55%
TTM Avg
11.67%
3Y Avg
11.80%
5Y Avg
12.59%
Market Cap
$1.65B
Gross Margin
66.15%
TTM Avg
69.48%
3Y Avg
67.43%
5Y Avg
67.56%
Market Cap
$1.63B
Gross Margin
87.11%
TTM Avg
89.24%
3Y Avg
90.16%
5Y Avg
89.75%
Market Cap
$1.62B
Gross Margin
51.01%
TTM Avg
55.14%
3Y Avg
57.28%
5Y Avg
56.79%
Market Cap
$1.79B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$1.61B
Gross Margin
53.89%
TTM Avg
45.92%
3Y Avg
-11.61%
5Y Avg
-9.29%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Personalis, Inc. (PSNL) | $1.70B | 22.65% | 14.97% | 25.59% | 25.17% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.70B | 76.47% | 79.35% | 79.86% | 39.87% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 49.52% | 50.81% | 52.12% | 52.25% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.73B | 12.55% | 11.67% | 11.80% | 12.59% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | 66.15% | 69.48% | 67.43% | 67.56% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.63B | 87.11% | 89.24% | 90.16% | 89.75% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 51.01% | 55.14% | 57.28% | 56.79% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.79B | 100.00% | 100.00% | 100.00% | 100.00% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.61B | 53.89% | 45.92% | -11.61% | -9.29% |
| Absci Corporation (ABSI)vs › | $1.79B | -319.36% | -798.46% | -813.46% | -704.28% |
Gross Margin
22.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 21.21% |
| 2026-03-31 | 1.82% |
| 2025-12-31 | 10.95% |
| 2025-09-30 | 13.20% |
| 2025-06-30 | 27.65% |
| 2025-03-31 | 34.98% |
| 2024-12-31 | 27.08% |
| 2024-09-30 | 34.02% |
| 2024-06-30 | 35.59% |
| 2024-03-31 | 28.13% |
| 2023-12-31 | 26.45% |
| 2023-09-30 | 19.08% |
| 2023-06-30 | 28.70% |
| 2023-03-31 | 25.08% |
| 2022-12-31 | 13.83% |
| 2022-09-30 | 16.68% |
| 2022-06-30 | 23.47% |
| 2022-03-31 | 28.09% |
| 2021-12-31 | 38.66% |
| 2021-09-30 | 36.23% |
| 2021-06-30 | 37.69% |
| 2021-03-31 | 35.57% |
| 2020-12-31 | 30.09% |
| 2020-09-30 | 26.91% |
| 2020-06-30 | 23.97% |
| 2020-03-31 | 21.08% |
| 2019-12-31 | 36.16% |
| 2019-09-30 | 32.82% |
| 2019-06-30 | 37.30% |
| 2019-03-31 | 28.31% |
| 2018-12-31 | 36.70% |
| 2018-09-30 | 38.45% |
| 2018-06-30 | 27.23% |
| 2018-03-31 | 2.38% |
